Adecto Pharmaceuticals www.adectopharma.com
Adecto Pharmaceuticals identified a critical driver of tumor growth and metastasis and is developing antibody-based therapeutics against triple-negative breast cancer and other aggressive malignancies.
Gail Sonenshein, President; Nora Mineva, CSO
Developing the next generation of bead-based bioassays, which employ mass spectrometry and optical imaging to facilitate high information content proteomic research.
Vladislav Bergo, CEO
Cellanyx Diagnostics LLC www.cellanyx.com
Developing in vitro tissue and cell culturing techniques for use in research and in vitro diagnostics, specifically prognostic information for prostate cancer treatment decisions.
Ashok Chander,CEO; Mani Foroohar,CSO
Cell Assay Innovations, Inc. www.cellassayinnov.com
A biotechnology service company dedicated to cell-based assay technology development with a focus on proprietary kinase assay panels for drug screening and other cell culture services.
Deborah Moshinsky, President; LiPing Wu, CSO
Genomic Expression www.genomicexpression.com
Offers a proprietary OneRNA™ technology platform that dramatically simplifies quantitative RNA-sequencing, using proprietary algorithms and databases, assisting the clinical development of new cancer drugs with a focus on immune therapies.
Gitte Pederson, CEO; Tanya Kanigan, CTO
Glycologix LLC (under construction)
Developing a novel suite of engineered proteoglycan-mimics designed to assist in the healing and restoration of soft tissue extracellular matrix compromised by age, injury or medical disorder.
Vince Novak, CEO & Co-Founder; Tom Jozefiak, Co-Founder & CSO
Offers pharmaceutical and biotech companies reliable and efficient access to small molecule metabolites in order to accelerate drug R&D and reduce costs.
Marc Bazin, President; Ryan Buzdygon, Director of Operations
iHope Network www.ihopenetwork.com
iHope Network (IHN) uses its network of certified licensed clinicians to deliver technology-guided Cognitive Behavioral Therapy (CBT) treatment via phone and video conferencing.
Tom Hunter, CEO; Paul Earl, COO
Developing a neurostimulator device to mitigate insomnia.
Peter Kelley, Founder; John Douglas, Consultant
IVIVA Medical, Inc. (website under construction)
Developing bioengineered autologous dialysis grafts, an “implantable artificial kidney,” to substitute for, augment, or replace human kidney function without hemodialysis or the need for immunosuppression.
Harald Ott, MD, President & CEO; Charles Klassen, Research Scientist
Lariat Biosciences (website under construction)
Developing a non‐invasive diagnostic to detect early signs of cancer based on circulating DNA fragments arising from the death of tumor cells which carry the mutant genetic signature that gave rise to the abnormal growth.
Jonathan Larson, CEO
OWLife Technologies (website under construction)
Developed a virtual reality platform designed to empower people diagnosed with diabetes to better manage their disease and their lives. This approach offers a peer community and individualized simulation (avatar) experiences coupled with shared telemedicine group visits led by medical experts.
Suzanne Mitchell, MD, CEO
RAN Biotechnologies, Inc. www.ranbiotechnologies.com
Designs and manufacture two types of materials: (1) Solid Resins for selective capture and controlled release of viruses, bacteria, and proteins. Examples of related applications are viral clearance, vaccine purification, fluid disinfection and diagnostics; (2) FluoroSurfactants for droplet microfluidics.
Roger Nassar, CEO
seqWell, Inc. www.seqwell.com
Offers a DNA sequencing service called kiloSEQ ™, based on novel and proprietary technology that will enable high-quality, long-read sequencing of plasmids and amplicons for development of therapeutic biologicals and synthetic biology applications.
Joseph Mellor, CEO; Jack Leonard, Head of Operations
Thrive Bioscience, Inc. www.thrivebio.com
Is developing Smart Incubation Systems™ that will automatically monitor, maintain, passage, and assay cell and tissue culture.
Alan Blanchard, CSO; Thomas Farb, COO/CFO; Brian Foley, VP of Engineering & Manufacturing
TriBiotica’s proprietary technology uses the tumor’s unique genetic signature to force the tumor cells to assemble novel immune targets that would not be naturally produced, but which allows specific elimination of tumor cells
Jim Kurnick, MD, Chairman; Matt Lawlor, President; Ian Dunn, CTO; Estelle Newton
VirTech Bio (website under construction)
Develops innovative therapies for organ and tissue preservation, ex-vivo organ management and biomarker discovery using a technology platform combining machine perfusion with a new hemoglobin-based oxygen carrier solution.
Joseph Tucker, President; W.R. Light, VP R&D